Clinical trial
Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage…
NCT00280150 · UNC Lineberger Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00280150 |
|---|---|
| Title | Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer |
| Official title | Phase I/II Trial of Induction Carboplatin/Paclitaxel With Bevacizumab Followed by Concurrent Thoracic Conformal Radiation Therapy With Carboplatin/Paclitaxel, Bevacizumab and Erlotinib in Stage IIIA/B Non-Small Cell Lung Cancer |
| Lead sponsor | UNC Lineberger Comprehensive Cancer Center, Other |
| Collaborators | Genentech, Inc. Industry Eli Lilly and Company |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Biological, Drug, Radiation |
| Interventions | bevacizumab, carboplatin, erlotinib hydrochloride, paclitaxel, 3-dimensional conformal radiation therapy |
| Enrollment | 46 |
| Start date | Jan 1, 2006 |
| Primary completion | Jan 1, 2012 |
| Completion | Jan 1, 2013 |
| First posted | Jan 20, 2006 |
| Last update posted | Jun 19, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: